Kazia Therapeutics Ltd (NASDAQ: KZIA) is running for the top in the market this morning, and for good reason. The comapny announced that the FDA has granted it Rare Pediatric Disease Designation. Here’s what’s going on:
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
KZIA Stock Rockets On Rare Pediatric Disease Designation
In the release, Kazia Therapeutics said that the US FDA has awarded Rare Pediatric Disease Designation for its paxalisib treatment candidate. The treatment is being developed as a potential option for Diffuse Intrinsic Pontine Glioma, a rare, yet highly-aggressive childhood brain cancer.
Read more at Alpha Stock News!